Mind-body therapies like meditation, psychotherapy, and deep breathing may help reduce stress levels, potentially reducing ...

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

The mainstay of treatment for urticaria is oral antihistamines as they reduce itch, wheal duration and numbers. Management is better achieved by taking antihistamines daily, not just when the ...

Xolair has gained EU approval as the first ever add-on therapy to treat chronic spontaneous urticaria (CSU) in adult and adolescent patients with inadequate response to H1-antihistamine treatment.

A new study published in the Journal of Allergy and Clinical Immunology showed that effective therapy for chronic spontaneous urticaria (CSU) may lower mortality. Between 0.5% and 1% of people have ...

One of Pledger’s specialties is building hives and frames — what beekeepers call woodware — from cypress harvested in North and South Carolina. He’s won awards for his designs and has ...

EVO-756 is under clinical development by Evommune and currently in Phase II for Chronic Urticaria Or Hives. According to GlobalData, Phase II drugs for Chronic Urticaria Or Hives have a 52% phase ...

Remibrutinib is under clinical development by Novartis and currently in Phase III for Chronic Urticaria Or Hives. According to GlobalData, Phase III drugs for Chronic Urticaria Or Hives have a 67% ...

RPT904 is being developed as a potential alternative to omalizumab, also known as Xolair, for the treatment of allergic conditions such as asthma, chronic spontaneous urticaria, chronic ...

The biotech predicts that the development of the antibody in chronic spontaneous urticaria, another indication in which Xolair is approved, could add another $1 billion in revenue. The forecasts ...

Xolair (omalizumab) is a prescription drug used to treat certain conditions, such as asthma or food allergies. The drug comes as an injection. It’s usually given once every 2 or 4 weeks. Xolair ...

InflaRx has commenced a Phase 2a study for INF904 in chronic spontaneous urticaria and hidradenitis suppurativa, dosing its first patient. InflaRx N.V. has announced the initiation of a Phase 2a ...